OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.
By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.
ERR pan-agonist. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Research study dose | 50 mg/kg weight-based | daily | Set by body weight — can't be turned into a single amount to draw | |||
| Community reported | 250 mcg | 1× daily | 0.125 mL | 12.5 u | 20 doses | |
| Community reported upper | 500 mcg | 1× daily | 0.25 mL | 25 u | 10 doses | |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial | |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 250 mcg | daily | 0.125 mL | 12.5 u | 14 | 3.5 mg |
| Week 3 onward per 4 weeks from here on |
500 mcg | daily | 0.25 mL | 25 u | 28 | 14 mg |
An estrogen-related receptor pan-agonist described as an exercise mimetic in preclinical models. Not a peptide, no human data of any kind. Reported doses below are the weight-based research figures, given raw rather than converted, because a human-equivalent conversion is not supported.
Buy SLU-PP-332this peptideOpens optimal-pep.com in a new tab
Browse the full catalogue, or jump to a neighbouring compound.
A small-molecule NNMT inhibitor rather than a true peptide. Research data show reduced adiposity in diet-induced obesity models. N…
A vascular-targeting peptidomimetic that ablates white adipose vasculature. Research studies showed weight loss alongside dose-dep…
Every compound compared in one table: dose range, how often, half-life and evidence tier.